Friday, 19 Jan 2018

You are here

New Zoster Vaccine Recommended by FDA Panel

Reuters reports that the Food and Drug Administration (FDA) advisory panel has voted 11-0 in favor of the safety and efficacy and ultimate approval of GlaxoSmithKline’s Shingrix shingles vaccine for use in adults aged 50 and over.

The proposed inactive vaccine against H. zoster (HZ) was previously reported to be more effective than the current live vaccine Zostavax made by Merck. (

The herpes zoster beta subunit vaccine was shown to be more than 90% effective (for 4+ years) in HZ prevention and post-herpetic neuralgia prevention, especially in those over age 70 yrs. - claims that exceed that seen with the current vaccine. 

Shingrix has the advantage of being an inactive (non-live) virus vaccine - that can be given to those who are immunosuppressed or receiving TNF inhibitors or other biologic agents.  Shingrix has not been studied in those who are immunosuppressed or receiving TNF inhibitors or other biologic agents.

GSK is forecasting sales for this product to reach $1 billion by 2023. In contrast, Zostavax, approved in 2006, is expected to generate sales of about $730 million this year. 

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Prevention of HBV Infection: How Are We Doing?

In 2016 the WHO set out to eliminate HBV infection as a public health threat by 2030. So far, we are far from this goal as vaccine implementation has been suboptimal in a number of important patient populations, including patients with rheumatologic diseases, as well as other immunocompromising diseases like HIV.

B Cell Changes Predict Autoimmunity with Checkpoint Inhibitors

The Journal of Clinical Investigation reports results of a study showing that increases in CD21lo B cells and plasmablasts following that combination checkpoint blockade preceded the onset of immune-related adverse events.

While some have postulated that IRAEs are thought to be T cell mediated, B cells have also been implicated. Investigators studied 39 melanoma patients undergoing treatment with either anti-CTLA4 or anti-PD1, or combination CCB therapy. They analyzed changes in circulating B cells before and after the first cycle of therapy of immune checkpoint blockade (23 received combination therapy, 8 received anti-CTLA4, and 8 received anti-PD1).

Ibuprofen’s Anti-androgenic Effect May Result in Hypogonadism in Males

PNAS reports use of ibuprofen by males may result in antiandrogen effects that may contribute to adult male reproductive problems.

Sorting Out the Complexities of Autoimmunity with Immune Checkpoint Inhibitor Therapy

An editorial and systematic review of complications seen when checkpoint inhibitor (CPI) therapies are given to patients with immune mediated inflammatory disorders (IMIDs) and cancer shows that nearly 75% manifest autoimmune and inflammatory immune-related adverse events (irAEs).

Baseline Risk Score Predicts Serious Infection Risk in TNF-Treated RA Patients

Curtis and colleagues have analyzed the certolizumab (CZP) RAPID1 and RAPID2 trials to assess the risk of serious infectious events (SIEs), and shown that steroids combined with an age-adjusted comorbidity index (AACI) yields a 2-3 fold predictable risk for SIE.